PMID- 27162008
OWN - NLM
STAT- MEDLINE
DCOM- 20171218
LR  - 20221207
IS  - 1872-6844 (Electronic)
IS  - 0920-1211 (Linking)
VI  - 124
DP  - 2016 Aug
TI  - Levetiracetam-induced cutaneous adverse drug reactions were not associated with 
      HLA genes in a small sample of Chinese patients with epilepsy.
PG  - 12-5
LID - S0920-1211(16)30055-9 [pii]
LID - 10.1016/j.eplepsyres.2016.04.008 [doi]
AB  - PURPOSE: This study aimed to evaluate the clinical characteristics of 
      levetiracetam (LEV)-induced cutaneous adverse drug reactions (cADRs) and to 
      explore its possible genetic association with the human leukocyte antigen (HLA) 
      genes. METHODS: Nine cases with LEV-induced cADRs were recruited. Demographic and 
      clinical information of these cases was summarized. Additionally, cases were 
      matched with LEV-tolerant controls (1:4). High-resolution HLA class I and class 
      II genotyping was performed for each participant. The allele frequencies between 
      the cases and controls were compared. RESULTS: All LEV-induced cADRs were mild 
      skin rashes which occurred within 28 days of LEV exposure. The mean latency from 
      LEV exposure to skin rash was (15.67+/-5.41) days (ranging 6-27). The carrier rates 
      of the two alleles, HLA-DRB1*0405 and HLA-DQB1*0401, were higher in cases 
      compared with controls (the same P=0.036, OR=13.875, 95% CI: 1.273-151.230). The 
      association between the HLA-C*0304 allele and LEV-induced cADRs was boundary 
      (P=0.05, OR=5.2, 95% CI: 1.086-24.897). However, the above-mentioned HLA alleles 
      didn't reach statistical significance after multiple comparisons. CONCLUSIONS: 
      Safety monitoring was necessary within four weeks after the initiation of LEV 
      treatment, although it has been regarded as a safe antiepileptic drug. Our study 
      failed to show any potential link between HLA alleles and LEV-induced cADRs in 
      Han Chinese. Further studies are needed to clarify the genetic and immunological 
      mechanisms of LEV-induced cADRs.
CI  - Copyright (c) 2016 Elsevier B.V. All rights reserved.
FAU - Hu, Fa-Yun
AU  - Hu FY
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, China.
FAU - Ren, Jie-Chuan
AU  - Ren JC
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, China.
FAU - An, Dong-Mei
AU  - An DM
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, China.
FAU - Chen, Jia-Ni
AU  - Chen JN
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, China.
FAU - Zhou, Dong
AU  - Zhou D
AD  - Department of Neurology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan Province, China. Electronic address: zhoudong66@yahoo.de.
LA  - eng
PT  - Journal Article
DEP - 20160502
PL  - Netherlands
TA  - Epilepsy Res
JT  - Epilepsy research
JID - 8703089
RN  - 0 (Anticonvulsants)
RN  - 0 (HLA Antigens)
RN  - 44YRR34555 (Levetiracetam)
RN  - ZH516LNZ10 (Piracetam)
SB  - IM
MH  - Adult
MH  - Anticonvulsants/*adverse effects/therapeutic use
MH  - Asian People
MH  - Child
MH  - China
MH  - Epilepsy/*drug therapy/genetics
MH  - Exanthema/*chemically induced/*genetics
MH  - Female
MH  - Gene Frequency
MH  - Genotyping Techniques
MH  - HLA Antigens/*genetics
MH  - Heterozygote
MH  - Humans
MH  - Levetiracetam
MH  - Male
MH  - Middle Aged
MH  - Piracetam/adverse effects/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Cutaneous adverse drug reactions
OT  - Epilepsy
OT  - Human leukocyte antigen
OT  - Levetiracetam
OT  - Rash
EDAT- 2016/05/11 06:00
MHDA- 2017/12/19 06:00
CRDT- 2016/05/11 06:00
PHST- 2015/05/04 00:00 [received]
PHST- 2016/04/10 00:00 [revised]
PHST- 2016/04/30 00:00 [accepted]
PHST- 2016/05/11 06:00 [entrez]
PHST- 2016/05/11 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
AID - S0920-1211(16)30055-9 [pii]
AID - 10.1016/j.eplepsyres.2016.04.008 [doi]
PST - ppublish
SO  - Epilepsy Res. 2016 Aug;124:12-5. doi: 10.1016/j.eplepsyres.2016.04.008. Epub 2016 
      May 2.